Cellectar Biosciences Current Ratio vs. Current Valuation
| CLRB Stock | USD 4.34 0.08 1.81% |
Current Ratio | First Reported 2010-12-31 | Previous Quarter 2.58318063 | Current Value 2.45 | Quarterly Volatility 4.52676869 |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.39 | 0.44 |
|
|
For Cellectar Biosciences profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Cellectar Biosciences to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Cellectar Biosciences utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Cellectar Biosciences's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Cellectar Biosciences over time as well as its relative position and ranking within its peers.
Cellectar | Build AI portfolio with Cellectar Stock |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cellectar Biosciences. If investors know Cellectar will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cellectar Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Cellectar Biosciences is measured differently than its book value, which is the value of Cellectar that is recorded on the company's balance sheet. Investors also form their own opinion of Cellectar Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Cellectar Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cellectar Biosciences' market value can be influenced by many factors that don't directly affect Cellectar Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cellectar Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cellectar Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cellectar Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cellectar Biosciences Current Valuation vs. Current Ratio Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Cellectar Biosciences's current stock value. Our valuation model uses many indicators to compare Cellectar Biosciences value to that of its competitors to determine the firm's financial worth. Cellectar Biosciences is rated fifth in current ratio category among its peers. It is rated below average in current valuation category among its peers . At present, Cellectar Biosciences' Current Ratio is projected to slightly decrease based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Cellectar Biosciences' earnings, one of the primary drivers of an investment's value.Cellectar Current Valuation vs. Current Ratio
Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Cellectar Biosciences |
| = | 4.51 X |
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Cellectar Biosciences |
| = | (510.5 K) |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Cellectar Current Valuation vs Competition
Cellectar Biosciences is rated below average in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is currently estimated at about 802.23 Million. Cellectar Biosciences has negative current valuation of (510,497) contributing less than 1% to the industry.
Cellectar Biosciences Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Cellectar Biosciences, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Cellectar Biosciences will eventually generate negative long term returns. The profitability progress is the general direction of Cellectar Biosciences' change in net profit over the period of time. It can combine multiple indicators of Cellectar Biosciences, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -1.6 M | -1.7 M | |
| Operating Income | -51.8 M | -49.2 M | |
| Income Before Tax | -44.5 M | -42.3 M | |
| Total Other Income Expense Net | 7.3 M | 7.6 M | |
| Net Loss | -44.6 M | -42.4 M | |
| Income Tax Expense | 66 K | 69.3 K | |
| Net Loss | -44.6 M | -42.4 M | |
| Non Operating Income Net Other | 166.8 K | 158.4 K | |
| Net Loss | -25.7 M | -24.5 M | |
| Interest Income | 1.2 M | 681.6 K | |
| Net Interest Income | 1.2 M | 1.3 M | |
| Change To Netincome | 1.8 M | 1.9 M | |
| Net Loss | (1.22) | (1.28) | |
| Income Quality | 1.07 | 0.54 | |
| Net Income Per E B T | 1.00 | 0.63 |
Cellectar Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Cellectar Biosciences. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Cellectar Biosciences position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Cellectar Biosciences' important profitability drivers and their relationship over time.
Use Cellectar Biosciences in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cellectar Biosciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cellectar Biosciences will appreciate offsetting losses from the drop in the long position's value.Cellectar Biosciences Pair Trading
Cellectar Biosciences Pair Trading Analysis
The ability to find closely correlated positions to Cellectar Biosciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cellectar Biosciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cellectar Biosciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cellectar Biosciences to buy it.
The correlation of Cellectar Biosciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cellectar Biosciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cellectar Biosciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cellectar Biosciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Cellectar Biosciences position
In addition to having Cellectar Biosciences in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Technology Thematic Idea Now
Technology
Companies that are involved in development or distribution of technologically based goods and services such as software, IT or electronics. The Technology theme has 30 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Technology Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Trending Equities. For information on how to trade Cellectar Stock refer to our How to Trade Cellectar Stock guide.You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
To fully project Cellectar Biosciences' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Cellectar Biosciences at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Cellectar Biosciences' income statement, its balance sheet, and the statement of cash flows.